# Lipoprotein(a) Biochemistry > Lipoprotein(a) in MBBS Biochemistry: apo(a) kringle structure, plasminogen homology, cardiovascular risk thresholds and management options. - Canonical URL: https://prepelephant.com/topics/mbbs/biochemistry/lipoprotein-a - Exam / course: MBBS · Subject: Biochemistry - Publisher: PrepElephant (https://prepelephant.com) — Prepared and reviewed by the PrepElephant Academic Review Team - First published: 2026-10-02 - Last updated: 2026-10-02 - How to cite: "Lipoprotein(a) Biochemistry", PrepElephant, https://prepelephant.com/topics/mbbs/biochemistry/lipoprotein-a ## Direct answer Lipoprotein(a), or Lp(a), is an LDL particle to which a second glycoprotein, apolipoprotein(a), is attached by a disulfide bond to apo B-100. Apo(a) is structurally homologous to plasminogen, with multiple kringle IV repeats whose number — an inherited trait — sets the plasma concentration, so Lp(a) levels are essentially decided at birth. Because the kringle domains mimic plasminogen's fibrin-binding region, Lp(a) competes with plasminogen and tPA, impairs fibrinolysis, carries oxidised phospholipid, and behaves as both atherogenic and prothrombotic. Concentrations above roughly 50 mg/dL (about 125 nmol/L) mark an independent, genetically determined cardiovascular risk factor that is barely moved by statins. ## What you must remember - **Structure:** one LDL particle (apo B-100, cholesterol ester core) plus one apo(a) linked by a disulfide bridge; apo(a) is made in the liver and assembles with LDL extracellularly. - **Kringle IV copy number varies** from person to person; smaller apo(a) isoforms with fewer kringle IV repeats correlate with higher plasma concentrations and higher risk. - **Risk threshold:** values above about 50 mg/dL (over ~125 nmol/L in molar units — the two units are not interchangeable, so follow your laboratory's assay) roughly double cardiovascular risk; measurement need not be fasting. - **Genetically fixed:** lifestyle and statins change Lp(a) little; niacin lowers it by up to roughly a third and PCSK9 inhibitors by about a fifth to a quarter, but no agent is approved yet specifically to lower Lp(a). - **Antisense and siRNA agents** (pelacarsen, zerlasiran, olpasiran among them) lower Lp(a) substantially; the large pelacarsen outcomes trial reported in 2026 missed its primary cardiovascular endpoint, and outcome evidence for the class remains unsettled — a fast-moving field to quote with a date. - **When to suspect high Lp(a):** premature myocardial infarction or stroke without conventional risk factors, familial hypercholesterolaemia (frequent co-traveller), aortic valve stenosis (Lp(a) is an identified risk marker), and unexplained high LDL refractory to statins. - **Confounding states:** levels rise in nephrotic syndrome, chronic kidney disease and pregnancy; they fall in severe liver disease — interpret alongside albumin and LFTs. ## A premature-MI work-through A 38-year-old non-smoking man, lean and non-diabetic, survives an anterior wall myocardial infarction. His LDL is 150 mg/dL, HDL normal, and there is a strong history of early coronary disease in two uncles. The one measurement most often skipped in Indian clinics is Lp(a); ordered here, it returns 92 mg/dL. The interpretation writes itself: this is a genetically determined, lifelong exposure, his siblings each carry roughly a one-in-four chance of a similar level, and cascade screening of the family is justified once — a single measurement suffices for life because levels are stable. Management does not wait for Lp(a)-specific drugs: high-intensity statin therapy to drive LDL as low as possible (the risk of Lp(a) falls substantially when coexisting LDL burden is reduced), aspirin, risk-factor control, and lipoprotein apheresis in select countries for extreme values with recurrent events. He should also have an aortic valve surveillance echo, given the stenosis association. ## How the examiner frames it Two traps recur. The first: "statin therapy raised my patient's Lp(a) — what happened?" Statins can modestly increase Lp(a) percentage-wise while lowering absolute LDL; the net effect is strongly favourable, and this is a discussion point, never a reason to stop therapy. The second: units. Papers quote mg/dL and nmol/L interchangeably at students' peril, because apo(a) size makes conversion non-linear — always state which assay your lab reports. A third favourite is the plasminogen link: candidates who say "Lp(a) causes thrombosis by inhibiting fibrinolysis" score, those who say "it is just LDL" do not. ## Frequently asked questions ### What is the structural relationship between apo(a) and plasminogen? Apo(a) shares homology with plasminogen, including kringle IV-like repeats, and competes with plasminogen for fibrin binding, impairing clot lysis. ### At what level is Lp(a) considered high-risk? Above approximately 50 mg/dL (about 125 nmol/L), with risk rising further in the top quintile; one lifetime measurement is sufficient. ### Does statin therapy lower Lp(a)? No — statins mainly lower LDL; any small Lp(a) rise is outweighed by benefit, so aggressive LDL lowering remains the treatment backbone. ### Which non-lipid condition is associated with elevated Lp(a)? Calcific aortic valve stenosis, where Lp(a)-associated oxidised phospholipids are deposited in the valve leaflets. ### Should family members of a patient with high Lp(a) be tested? Yes — because levels are inherited, cascade screening of first-degree relatives identifies others at premature cardiovascular risk.